Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel versus levetiracetam for tumour-associated epilepsy in grade II-III glioma
ACTRN12617000078358Phase 2Terminated
- Sponsor
- Melbourne Health
- Start
- Jul 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy and glioma comparing Perampanel with Levetiracetam (2 arms). Primary endpoints: Proportion seizure-free for at least 24 continuous weeks during assessment phase and Time to first seizure during assessment phase. Started Jul 2017; status: terminated.
02
Drugs
perampanellevetiracetam
03
Conditions
epilepsyglioma
Beyond the preview
Go deeper on ACTRN12617000078358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000078358.